Q-omics provides the consensus-scored KRT223P profile across patient tissues and cancer cell-line models. KRT223P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KRT223P is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, KRT223P RNA expression shows 6,807 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, KIRC, and STAD as cancer lineages where KRT223P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT223P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT223P survival associations across molecular data types. KRT223P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT223P RNA expression–survival associations across cancer types. High KRT223P expression shows unfavorable associations in KIRP, DLBC, UVM and COAD, but favorable associations in SARC and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KIRP as the clearest survival context for KRT223P RNA expression.
This table summarizes KRT223P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT223P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT223P shows lower tumor expression in KICH, HNSC, COAD and STAD and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher KRT223P RNA expression in tumor versus normal tissue (log2 FC = +2.782, t-test p < 0.001).
This table shows molecular features associated with KRT223P in patient tissues and cancer cell lines. In patient samples, KRT223P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
